Hydantoins: Structure, Pharmacology, and Clinical Use of Phenytoin and Derivatives

Hydantoins (imidazolidine-2,4-diones) are heterocyclic compounds with a five-membered ring containing two nitrogens and two carbonyl groups. Phenytoin, the prototype anticonvulsant, has defined this drug class for decades.

Chemical Structure

  • Core: Imidazolidine-2,4-dione (cyclic ureide)
  • 5-position substitution (phenyl in phenytoin) confers anticonvulsant activity
  • pKa ~8.3; weak acid; poorly water-soluble (parenteral forms require propylene glycol/ethanol at pH 12)

Pharmacology

Mechanism of Action (Phenytoin)

  • Use-dependent blockade of voltage-gated sodium channels → stabilizes neuronal membranes, limits high-frequency repetitive firing
  • No effect on normal synaptic transmission at therapeutic doses

Pharmacokinetics

  • Oral absorption: slow, erratic (pH-dependent, saturable)
  • Protein binding: ~90% to albumin; free fraction is pharmacologically active
  • Metabolism: Hepatic CYP2C9/2C19 → p-HPPH glucuronide
  • Zero-order kinetics at therapeutic doses (enzyme saturation) → small dose changes produce large plasma level changes
  • Half-life: 12–36 hours (dose-dependent)
  • Induces CYP3A4, CYP2C → numerous drug interactions

Clinical Uses

  • Phenytoin: Focal and generalized tonic-clonic seizures; status epilepticus; neurosurgery prophylaxis. Not for absence or myoclonic seizures.
  • Fosphenytoin (prodrug): IV/IM administration; safer, faster, no propylene glycol
  • Mephenytoin (historical): CYP2C19 probe substrate
  • Dantrolene (hydantoin derivative): Malignant hyperthermia, spasticity (ryanodine receptor antagonist)

Adverse Effects

  • Acute: Nystagmus, ataxia, dysarthria (dose-related); IV hypotension/arrhythmia (propylene glycol vehicle)
  • Chronic: Gingival hyperplasia (30–50%), hirsutism, coarsening facial features, osteomalacia (vitamin D catabolism), folate deficiency, peripheral neuropathy
  • Idiosyncratic: SJS/TEN, DRESS syndrome, hepatitis, lupus-like syndrome, cytopenias

Therapeutic Drug Monitoring

  • Total: 10–20 µg/mL; Free: 1–2 µg/mL (preferred in hypoalbuminemia, renal failure, pregnancy)
  • Trough levels; adjust for protein binding: Corrected = Measured / [(0.1 × albumin) + 0.1]

Lyme Disease - Related Articles